Walmart has agreed to pay a $50 million settlement following allegations from the Department of Justice (DOJ) and Drug Enforcement Administration (DEA) that its pharmacies illegally filled thousands of prescriptions for opioids and other controlled substances [1]. The government complaint, initially filed at the end of President Donald Trump’s first term and amended during President Joe Biden’s term, accused Walmart of violating the Controlled Substances Act by filling invalid prescriptions with the knowledge of both pharmacists and the company’s compliance team since June 2013 [1].
According to the DOJ, some Walmart pharmacists reported the alleged illegal activity to the corporate compliance team through thousands of 'refusal-to-fill' forms. However, the compliance team was accused of prioritizing sales and patient awareness over compliance with the Controlled Substances Act. An internal email cited by the DOJ indicated that the compliance team considered 'driving sales and patient awareness' a better use of time than analyzing refusal-to-fill reports [1].
The complaint further alleged that pharmacists knowingly filled prescriptions from 'pill mill' prescribers or those with red flags, such as dangerous drug combinations, repeated early fill requests, or high-dosage opioid prescriptions [1]. As part of the settlement, Walmart has agreed to establish a hotline for employees and patients to report suspected illegal activity and to proactively monitor pharmacy dispensing patterns [1].
On the day of the announcement, Walmart's stock (WMT) closed at $103.09, up $0.46 or 0.45% [1].
CONCLUSION
Walmart's $50 million settlement addresses serious allegations regarding its pharmacy practices and opioid prescription compliance. The company has committed to new monitoring and reporting measures as part of the agreement. Despite the legal resolution, Walmart's stock showed a modest gain, suggesting limited immediate negative market reaction.